Institution where the study was performed: Departments of Internal Medicine and Urology, University of Michigan Medical School, Ann Arbor, MI.
Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families†
Article first published online: 13 JAN 2005
Copyright © 2005 Wiley-Liss, Inc.
Volume 64, Issue 1, pages 60–66, 15 June 2005
How to Cite
Bock, C. H., Peyser, P. A., Montie, J. E. and Cooney, K. A. (2005), Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. Prostate, 64: 60–66. doi: 10.1002/pros.20220
- Issue published online: 13 MAY 2005
- Article first published online: 13 JAN 2005
- Manuscript Accepted: 28 SEP 2004
- Manuscript Received: 22 JUL 2004
- National Human Genome Research Institute. Grant Number: T32 HG00040
- S.P.O.R.E. in Prostate Cancer. Grant Number: P50 CA69568
- National Institutes of Health. Grant Numbers: CA79596, CA72818, CA15083
- University of Michigan Comprehensive Cancer Center
- hereditary neoplastic syndromes;
- prostate specific antigen (PSA);
- age factors
The decline in age at prostate cancer diagnosis over the past decade is partially attributable to prostate specific antigen (PSA) screening. We examined age at diagnosis over successive generations within prostate cancer families.
Families with at least two affected men were selected from the University of Michigan Prostate Cancer Genetics Project. The 1,345 individuals from 489 families were grouped into three generations.
Risk of prostate cancer diagnosis at a given age was estimated to increase 1.31 (95% CI: 1.13–1.51) times from one generation to the next. Among men diagnosed prior to the PSA era, inferences were similar (hazard ratio = 1.28, 95% CI: 0.97–1.68). No maternal versus paternal disease transmission effect was observed.
Age at prostate cancer diagnosis was observed to decrease over successive generations in families from an ongoing familial prostate cancer study. This finding, if confirmed, may have important implications for familial prostate cancer risk assessment. © 2005 Wiley-Liss, Inc.